News
KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate. The Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to KYV-101 for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback